Primex Nears Market With Oral Pediatric Sedation Solution
Switzerland’s fast-growing critical-care company Primex has submitted for approval what it believes is the first oral solution for the mild to moderate sedation of anxious children undergoing surgical and diagnostic procedures, with a launch in Europe penciled in for a year’s time.
You may also be interested in...
Also, Advicenne doubles its fundraising to date; Michael Gilman-helmed Arrakis raises a $38m Series A; Breath spins out with $46m; and Spero gets $51.7m for novel antibacterials.
La Jolla Pharmaceutical grossed $125m, Inspyr Therapeutics signs a deal to raise up to $100m, Ionis's Akcea makes $100m IPO plans, and $64m in cash for SutroVax tops recent venture capital rounds.
A group of Belgian and South Korean investors are providing series B funding to support an early-stage clinical study of an off-the-shelf cancer immunotherapy candidate based on an allogeneic plasmacytoid dendritic cell line.